I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Description

The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.

Conditions

COVID-19

Study Overview

Study Details

Study overview

The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.

I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Condition
COVID-19
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294

Davis

UC Davis Medical Center, Davis, California, United States, 95817

Irvine

UC Irvine Medical Center, Irvine, California, United States, 92868

Long Beach

Long Beach Memorial Medical Center, Long Beach, California, United States, 90806

Los Angeles

Kaiser LAMC, Los Angeles, California, United States, 90027

Los Angeles

University of Southern California, Los Angeles, California, United States, 90033

Newport Beach

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States, 92663

San Francisco

University of California San Francisco (UCSF), San Francisco, California, United States, 94115

Aurora

University of Colorado, Aurora, Colorado, United States, 80045

New Haven

Yale Cancer Center, New Haven, Connecticut, United States, 06510

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    QuantumLeap Healthcare Collaborative,

    Carolyn Carolyn, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

    Kathleen D Liu, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

    Laura Esserman, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

    Study Record Dates

    2030-07-31